Abbvie, Gubra ENTER HOME The license agreement to develop GUB014295

Brussels/Frankfurt/Paris (DPA-AFX) -ABBVIE (ABBV) and Gubra A/S have announced a license agreement to develop GUB014295, a long-acting amilin potential for the treatment of obesity. Abbvie will conduct development and marketing activities of GUB014295 globally. Gubra will receive $ 350 million in total payment in advance and will be eligible to receive up to $ 1.875 billion, commercial payments and sales with global net sales levels. GUB014295 is currently in a clinical study of phase 1.

Gubra, listed on Nasdaq Copenhagen, is specialized in pre-clinical contractual research services and the discovery of peptide-based drugs in metabolic and fibrotic diseases.

For more such health news, visit rttnews.com.